Compare · LMDX vs VNRX
LMDX vs VNRX
Side-by-side comparison of LumiraDx Limited (LMDX) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMDX and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 393.8x VNRX ($5.7M).
- VNRX has hit the wire 2 times in the past 4 weeks while LMDX has been quiet.
- Both have 4 recent analyst ratings on file.
- Company
- LumiraDx Limited
- VolitionRX Limited
- Price
- $0.02-53.80%
- $0.18-4.52%
- Market cap
- $2.23B
- $5.7M
- 1M return
- -
- -34.95%
- 1Y return
- -
- -98.03%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 0
- 2
- Recent ratings
- 4
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points
Latest VNRX
- Chief Commercial Officer Forterre Gael covered exercise/tax liability with 284 shares, decreasing direct ownership by 2% to 16,284 units (SEC Form 4) (tax liability)
- Chief Operating Officer Michel Gaetan covered exercise/tax liability with 608 shares, decreasing direct ownership by 5% to 12,232 units (SEC Form 4) to cover withholding tax
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
- VolitionRx Participates in Launch of DETECSEPS Program in France
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRX Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
- SEC Form EFFECT filed by VolitionRX Limited
- Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference